{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:13:43Z","timestamp":1790871223777,"version":"4.1.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T00:00:00Z","timestamp":1301011200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0018198","type":"journal-article","created":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T20:54:48Z","timestamp":1301086488000},"page":"e18198","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":46,"title":["HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts"],"prefix":"10.1371","volume":"6","author":[{"given":"Tapan K.","family":"Nayak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Garmestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Milenic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena E.","family":"Baidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Brechbiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,3,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis.","volume":"9","author":"H Yang","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.trsl.2009.01.004","article-title":"Asbestos-induced lung diseases: an update.","volume":"153","author":"DW Kamp","year":"2009","journal-title":"Transl Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma.","volume":"366","author":"BW Robinson","year":"2005","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1053\/j.seminoncol.2005.02.010","article-title":"New agents in the management of advanced mesothelioma.","volume":"32","author":"NJ Vogelzang","year":"2005","journal-title":"Semin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma.","volume":"353","author":"BW Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/cncr.22552","article-title":"Update on the molecular biology of malignant mesothelioma.","volume":"109","author":"AY Lee","year":"2007","journal-title":"Cancer"},{"key":"ref7","first-page":"333","article-title":"Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers.","volume":"152","author":"JC Pache","year":"1998","journal-title":"Am J Pathol"},{"key":"ref8","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor.","volume":"56","author":"CL Zanella","year":"1996","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/carcin\/21.12.2275","article-title":"Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres.","volume":"21","author":"SP Faux","year":"2000","journal-title":"Carcinogenesis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2010.01.002","article-title":"Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.","volume":"70","author":"R Gaafar","year":"2010","journal-title":"Lung Cancer"},{"key":"ref11","article-title":"EGFR And PDGFR Differentially Promote Growth In Malignant Epitheloid Mesothelioma Of Short- And Long-term Survivors.","author":"H Kothmaier","year":"2007"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.","volume":"54","author":"JG Edwards","year":"2006","journal-title":"Lung Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00432-008-0384-4","article-title":"Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.","volume":"134","author":"K Okuda","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.","volume":"51","author":"A Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.","volume":"25","author":"LL Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.","volume":"11","author":"R Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","article-title":"Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.","volume":"34","author":"CA Boswell","year":"2007","journal-title":"Nucl Med Biol"},{"key":"ref18","first-page":"115S","article-title":"Perspectives on cancer therapy with radiolabeled monoclonal antibodies.","volume":"46","author":"RM Sharkey","year":"2005","journal-title":"J Nucl Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1158\/1078-0432.CCR-10-0162","article-title":"Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.","volume":"16","author":"PL Zinzani","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1040-8428(00)00136-0","article-title":"Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies.","volume":"38","author":"CM Richman","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1089\/cbr.2006.21.88","article-title":"A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.","volume":"21","author":"JY Wong","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"ref22","first-page":"1663","article-title":"Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.","volume":"44","author":"I Verel","year":"2003","journal-title":"J Nucl Med"},{"key":"ref23","first-page":"1281","article-title":"PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels.","volume":"42","author":"A Lovqvist","year":"2001","journal-title":"J Nucl Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00259-004-1561-6","article-title":"Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.","volume":"31","author":"A Helisch","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ijc.25409","article-title":"PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A''-DTPA-bevacizumab.","volume":"128","author":"TK Nayak","year":"2011","journal-title":"Int J Cancer"},{"key":"ref26","first-page":"1818","article-title":"RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody.","volume":"36","author":"GW Philpott","year":"1995","journal-title":"J Nucl Med"},{"key":"ref27","first-page":"2363","article-title":"Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso.","volume":"36","author":"PD Cutler","year":"1995","journal-title":"J Nucl Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1078-0432.CCR-06-2300","article-title":"Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.","volume":"13","author":"DE Milenic","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2967\/jnumed.109.071290","article-title":"Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.","volume":"51","author":"TK Nayak","journal-title":"J Nucl Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s00259-009-1370-z","article-title":"PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A\u2019\u2019-DTPA-cetuximab.","volume":"37","author":"TK Nayak","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref31","first-page":"2635","article-title":"High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.","volume":"59","author":"TM Behr","year":"1999","journal-title":"Cancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2214\/ajr.172.4.10587144","article-title":"Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.","volume":"172","author":"RT Heelan","year":"1999","journal-title":"AJR Am J Roentgenol"},{"key":"ref33","article-title":"Volume-Based Parameter of (18)F-FDG PET\/CT in Malignant Pleural Mesothelioma Prediction of Therapeutic Response and Prognostic Implications.","author":"HY Lee","journal-title":"Ann Surg Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.","volume":"16","author":"AK Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.crad.2005.05.015","article-title":"Use of imaging in the management of malignant pleural mesothelioma.","volume":"60","author":"RE Benamore","year":"2005","journal-title":"Clin Radiol"},{"key":"ref36","first-page":"995","article-title":"PET for the evaluation of pleural thickening observed on CT.","volume":"45","author":"H Kramer","year":"2004","journal-title":"J Nucl Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma.","volume":"27","author":"AS Tsao","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics.","volume":"93","author":"ED Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics.","volume":"84","author":"W Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1158\/1078-0432.CCR-04-1226","article-title":"Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.","volume":"10","author":"DE Milenic","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0969-8051(02)00322-0","article-title":"A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin.","volume":"29","author":"K Garmestani","year":"2002","journal-title":"Nucl Med Biol"},{"key":"ref42","first-page":"viii, 494","article-title":"Pharmacokinetics.","author":"M Gibaldi","year":"1982"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0018198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T07:02:36Z","timestamp":1540278156000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0018198"}},"subtitle":[],"editor":[{"given":"Andrew","family":"Yeudall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,3,25]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,3,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0018198","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,25]]}}}